Hence, the disparity between studies may reflect the fact that these genetic variants have time-dependent effects on cognition which vary with disease stage: MAPT seems to have its greatest impact on cognitive decline in early PD, whereas APOE may have a more pronounced effect in later disease. Here, APOE is linked to Parkinson disease.